Secukinumab improves quality of life for patients with psoriasis
Click Here to Manage Email Alerts
BOSTON — Quality of life improvements were recorded in most pediatric patients with psoriasis who received secukinumab, according to a poster presented at the American Academy of Dermatology Annual Meeting.
“For pediatric patients with psoriasis, clearance or near clearance of skin symptoms is associated with the greatest improvements in quality of life,” John Browning, MD, of The University of Texas at San Antonio, and colleagues wrote. “Secukinumab rapidly improved skin symptoms as determined by PASI and quality of life as measured by [Children’s DLQI (CDLQI)] in children and adolescents with psoriasis. However, the relationships between achievements of categorical PASI responses and the extent of improvement in CDLQI have not been explored in these patients.”
Patients with severe plaque psoriasis aged 6 years to less than 18 years were stratified by weight and randomly assigned 1:1 to receive either low dose or high dose subcutaneous secukinumab for 52 weeks.
In the low dose groups, patients weighing less than 50 kg received 75 mg and those weighing 50 kg or more received 150 mg. In the high dose groups, the low dose of 75 mg was given to patients weighing less than 25 kg, a 150 mg dose was given to those weighing 25 to less than 50 kg and a 300 mg dose was given to those weighing 50 kg or more.
At week 52, 64.3% of the low dose cohort and 57.1% of the high dose cohort achieved clear or almost clear CDLQI and a 75% or greater reduction in PASI scores.
CDLQI 0/1 and 90% or greater reduction in PASI scores were achieved by 54.8% of both dosage groups, while a 100% reduction in PASI scores was recorded in 38.1% of the low dose cohort and 45.2% of the high dose cohort.
A similar number of patients achieved both CDLQI 0/1 and either [body surface area (BSA)] less than 3% or improvement of 75% or greater, while more than half achieved both CDLQI 0/1 and BSA less than 1%.
Collapse
Browning J, et al. Poster. Simultaneous improvements in skin signs and quality of life in pediatric patients with psoriasis receiving secukinumab over 52 weeks. Presented at: American Academy of Dermatology Annual Meeting; March 25-29, 2022; Boston.
Read more about
Click Here to Manage Email Alerts